Equasens Société anonyme (EQS) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 declined 4.1% year-over-year to €108.0M, with net income down 21.0% to €18.1M, mainly due to weaker hardware sales, higher costs, and ongoing investments in R&D, teams, and infrastructure.

• Operating margin fell to 19.4%–20.0%, reflecting increased personnel and external charges.

• Strategic investments in digital health, cloud infrastructure, and SaaS transition continue, aligning with public health digitalization programs.

• Major events included the acquisition of DIGIPHARMACIE (70%) and increased stake in PANDALAB to 91.25%.

• A tax audit for 2020–2021 is ongoing, with management confident of a favorable outcome.

Financial highlights

• Revenue: €108.0M in H1 2024, down from €112.6M in H1 2023 (-4.1%).

• Operating income: €20.9M, down from €27.5M (-24.1%).

• Net income: €18.1M, down from €22.9M (-21.0%).

• Earnings per share: €1.13, down from €1.45.

• Net cash position at period end: €88.0M, with a gearing ratio of -39.8%.

Outlook and guidance

• Management anticipates a return to revenue growth in H2 2024, with double-digit growth targeted from 2025.

• Acceleration of new product launches and international expansion planned for 2025–2026.

• Continued high investment in R&D, infrastructure, and human resources to support SaaS transition and European expansion.

• Anticipated improvement in economic conditions and continued focus on innovation and SaaS transition.